paravertebral block with ropivicaine
Phase 1Small molecule
paravertebral block with ropivicaine is one of 27 small molecule programs targeting Rib Fracture. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Rib Fracture
#DrugCompanyPhaseTrials
1Journavx
Vertex PharmaceuticalsApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Naropin
FFresenius Kabi Oncology Ltd.
Approved
Tylenol
KKenvue Brands
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Marcaine
IInnocoll
Approved
Ketalar
AAultman Health Foundation
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
Advil
KKenvue Brands
Approved
Opioid
Johnson & JohnsonApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGeorge Washington University